Kisqali (Ribociclib) 600 mg Daily Dose - 63 Film-Coated Tablets

Kisqali (ribociclib) is a targeted cancer medication indicated for the treatment of certain types of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

EGP 52,000

In Stock

Delivery to governorates within 3-4 working days

Easy returns within 14 days

Specifications

SKU	CT-76
Color	Luscious Blackberry

About the product›

About Kisqali (Ribociclib) 600 mg

Kisqali (ribociclib) is a kinase inhibitor designed to slow the progression of breast cancer by inhibiting specific proteins that fuel cancer cell growth. This 600 mg daily dose regimen is provided in a convenient pack containing 63 film-coated tablets.

Therapeutic Use and Dosage

The product is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. As indicated in the packaging, the 600 mg daily dose consists of three 200 mg tablets taken daily.

Key Product Features

Contents: 63 film-coated tablets organized into 3 individual weekly blister packs, with each pack containing 21 tablets (200 mg per tablet).
Formulation: Easy-to-swallow film-coated tablets for daily oral administration.
Manufacturer: Produced by Novartis, a leader in pharmaceutical innovation.

It is essential to follow the dosage regimen precisely as prescribed by your oncologist. Please consult the enclosed Medication Guide for comprehensive instructions on administration and potential side effects.